<DOC>
	<DOCNO>NCT02531308</DOCNO>
	<brief_summary>Evaluation impact metformin 2 year progression-free survival ( PFS ) rate subject previously untreated DLBCL add standard induction therapy . ( R-CHOP )</brief_summary>
	<brief_title>Metformin Combination With Standard Induction Therapy Large B-cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>Newly diagnose histologically confirm CD20 positive previously untreated diffuse large B-cell lymphoma receive 4-6 cycle ( 21 day cycle ) : R-CHOP : Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 ( cap @ 2mg ) Prednisone 100mg PO daily Days 1-5 Pegfilgrastim 6 mg subcutaneously within 72 start cycle Metformin 500 mg PO daily Cycle 1 Days 1-7 Metformin 500 mg PO twice daily Cycle 1 Days 7-21 Metformin 850 mg PO twice daily start day 22 continue throughout remainder cycle plus 22 day post treatment . Restaging do 4th cycle complete . Subjects monitor labs physical exam throughout study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Diagnosis Diffuse Large Bcell Lymphoma ( DLBCL ) document medical record histology base criterion establish World Health Organization a. subtyping require DLBCL 2 . No prior therapy diagnosis DLBCL 3 . Presence radiographically measurable lymphadenopathy extranodal lymphoid malignancy ( define presence equal great 1 lesion measure &gt; 1.5 cm long diameter &gt; 1.0 cm long perpendicular diameter assess CT MRI ) bone marrow involvement 4 . Eastern Cooperative Oncology Group performance score 02 5 . Life expectancy least 6 month 6 . No history medication dependent diabetes mellitus 7 . Required screen laboratory data ( within 4 week prior start study drug ) 1 . Patients already class antidiabetic medication include metformin , insulin analogue , sulfonylurea , thiazolidinediones ( TZDs ) incretinbased therapy clear need therapeutic intervention base fast blood glucose 2 . Known histological transformation indolent nonHodgkins Lymphoma ( NHL ) chronic lymphocytic leukemia ( CLL ) aggressive form NHL ( ie , Richter transformation ) 3 . Double triple hit lymphomas 4 . Known active cent4ral nervous system leptomeningeal lymphoma 5 . Presence known intermediate highgrade myelodysplastic syndrome 6 . History nonlymphoid malignancy within last 3 year ( see protocol exception ) 7 . Evidence ongoing systemic bacterial , fungal , viral infection time start study 8 . Ongoing , druginduced liver injury , chronic active Hepatitis C Virus ( HCV ) , chronic active Hepatitis B Virus ( HBV ) , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , ongoing extrahepatic obstruction cause cholelithiasis , cirrhosis liver , portal hypertension . 9 . HIV positive 10 . Ongoing inflammatory bowel disease 11 . Ongoing alcohol drug addiction 12 . Pregnancy 13 . History prior allogeneic bone marrow progenitor cell solid organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>diffuse large b-cell lymphoma ( DLBCL ) ,</keyword>
	<keyword>lymphoma</keyword>
</DOC>